Download Ongoing studies

Ongoing studies
Time interval: 2008 – 2010
Author title
Year of study
(S)
Country
Study design
USA
ClinicalTrials.gov
USA
ClinicalTrials.gov
Year of publication
(P) when available
Citicoline
Treatment of
Methamphetamine
Dependence.
ClinicalTrials.gov
Identifier:
NCT00950352
Start :January
2010;
Effects of
Modafinil in
Methamphetamine
Dependence
ClinicalTrials.gov
Identifier:
NCT00751023
Start : February
2009;
Expected
completion:
August 2011
Expected
completion: July
2010
Substance of dependence
(D)
Drugs of treatment (T)
Drugs for comparison (C)
Hypothesis (H)
Methamphetamine dependent
subjects treated with citicoline
will show significantly
reduced use of
methamphetamine as well as
use of other drugs (caffeine,
nicotine, alcohol, cocaine and
marijuana) compared to the
placebo treated group.
Medications which improve
cognitive deficits in
methamphetaminedependent individuals may
improve abstinence rates,
especially in the critical early
period of recovery. Modafinil
is an atypical stimulant
medication with evidence to
support its use in treating
cocaine dependence and
attention deficit/hyperactivity
disorder. The proposed
studies are designed to
evaluate modafinil as a
potential treatment for
methamphetamine
dependence and its cognitive
sequelae.
Patients N and
characteristics
N=111
N=60
Outcomes
Narrative
results
Risk
of
bias
Double-Blind
Placebo
Controlled Trial of
Aripiprazole for
Amphetamine
ClinicalTrials.gov
Identifier:
NCT00728312
Start: August
2009;
Dose Response of
Mirtazapine to
Methamphetamine
Induced Interest,
Mood Elevation
and Reward
NCT00600145
Start: September
2007
A Dose Ranging
Study of Modafinil
for
Methamphetamine
Dependence
NCT00630097
Start: December
2009
Modafinil for
Methamphetamine
Start: April 2009
USA
ClinicalTrials.gov
USA
ClinicalTrials.gov
USA
ClinicalTrials.gov
USA
ClinicalTrials.gov
Expected
completion: May
2014
Expected
completion: July
2010
Expected
completion:
December 2011
The purpose of this study is
to examine the efficacy of
aripiprazole (at a relatively
low dose of 5-15 mg per day),
as compared to placebo in a
prospective, double blinded
study in participants with
methamphetamine
dependence, in reducing the
use and craving for
methamphetamine. We
expect that aripiprazole will
significantly reduce the use of
methamphetamine as
measured by the changed in
the proportion of participant's
methamphetamine-free
weeks.
The primary purpose of this
study is to determine if
Mirtazapine will produce a
decrease in interest in the
drug, a decrease in mood
elevation, and/or a decrease
in reward when given before
methamphetamine compared
to placebo
Dependence
NCT00859573
Study of Medical
Treatment for
Methamphetamine
Addiction
Expected
completion: June
2010
Start: January
2009
Expected
completion: April
2012
Sources: http://clinicaltrials.gov
USA
ClinicalTrials.gov
Bupropion